Go-to-market strategy in digital health is not the same as go-to-market strategy in SaaS, consumer apps or general technology products.
In many startup environments, growth can be tested through direct acquisition, paid channels, fast onboarding and short feedback loops. A product is launched, users respond and the company iterates quickly.
Digital health follows a different logic.
A digital health startup may need to work with patients, clinicians, hospitals, payers, research institutions, insurers, employers or public health systems. Each of these stakeholders has different incentives, decision-making processes, risk concerns and adoption barriers.
That means the question is not only:
How do we acquire users?
The better question is:
How do we earn trust, prove value and enter the healthcare system through the right channel?
At GooVentures, we approach go-to-market in digital health as part of venture design, not as a marketing layer added after the product is built.
Why digital health go-to-market is different from SaaS
Many digital health startups begin with assumptions borrowed from traditional software growth.
They expect that if the product is useful, adoption will follow. They may focus on product launch, website conversion, inbound interest or early user acquisition before understanding how healthcare decisions are actually made.
This creates a common gap between product ambition and market reality.
In digital health, a product can be technically strong and still fail to scale if it does not answer critical adoption questions:
- Who is the real buyer?
- Who is the primary user?
- Who approves adoption?
- Who pays?
- Who carries risk?
- What evidence is needed before deployment?
- How does the product fit into existing workflows?
These questions are often more important than initial product visibility.
In digital health, go-to-market is less about pushing users through a funnel and more about aligning the people, evidence, workflows and incentives needed for adoption.
Start with the healthcare adoption pathway
Before defining channels, messaging or sales targets, founders need to understand the adoption pathway.
A digital health product may follow different go-to-market routes depending on who benefits, who uses it and who pays for it.
For example, a patient-facing app may rely on direct adoption. But if it requires clinical endorsement, reimbursement or integration into care pathways, the real market access route becomes more complex.
A provider-facing tool may need champions inside hospitals, evidence of workflow improvement, procurement approval, data security review and integration with existing systems.
A digital therapeutic may require clinical validation, regulatory positioning, payer conversations and medical credibility.
Each route is different.
The first task is to define the path clearly enough to avoid building a product for a market that cannot adopt it.
Common go-to-market models in digital health
Digital health startups often operate through one or more go-to-market models. Choosing the wrong model too early can create friction, while combining too many models can dilute focus.
| Go-to-market model | Typical buyer or channel | Key challenge |
| B2C | Patients or consumers. | Trust, engagement, retention and willingness to pay. |
| B2B | Healthcare organizations, employers or insurers. | Sales cycles, procurement and proof of value. |
| B2B2C | Institutions or payers enabling access to users. | Stakeholder alignment and adoption flow. |
| Provider-led | Clinics, hospitals or care teams. | Workflow fit and clinical credibility. |
| Payer-led | Insurers or reimbursement channels. | Evidence, cost-effectiveness and outcomes. |
| Pharma or medtech partnership | Industry partners. | Strategic fit, validation and scale requirements. |
There is no universally superior model.
The right model depends on the product, evidence stage, regulatory profile, user behavior and commercial logic of the venture.
Product-market fit in digital health is different
Product-market fit in digital health is not only about users liking the product.
A product may be useful to patients but irrelevant to payers. It may be valuable to clinicians but impossible to integrate into their workflow. It may generate engagement but lack evidence for institutional adoption.
In healthcare, product-market fit often requires alignment across three layers.
User value
The product must solve a real problem for the person using it.
Clinical or operational relevance
The product must make sense inside real care delivery or healthcare operations.
Economic or institutional logic
The product must create value for the stakeholder who pays, approves or scales it.
If one of these layers is missing, adoption becomes fragile.
Evidence is a go-to-market asset in digital health
In digital health, evidence is not only a scientific requirement.
It is a market access asset.
Investors, hospitals, providers, payers and strategic partners often want to see more than product functionality. They want to understand whether the product creates measurable value.
That value may relate to:
- Better patient outcomes.
- Reduced costs.
- Improved adherence.
- Workflow efficiency.
- Earlier detection.
- Better monitoring.
- Lower readmission risk.
The specific evidence depends on the product category.
But the principle is consistent: claims need support.
A go-to-market strategy that does not include an evidence strategy is incomplete.
Pilot programs as a path to market access
Pilot programs are often the bridge between early product validation and broader adoption.
In digital health, pilots are not just tests. They are structured opportunities to demonstrate value in real environments.
A strong pilot should define:
- The problem being tested.
- The users involved.
- The environment of deployment.
- The outcomes being measured.
- The data that will be collected.
- The decision criteria after completion.
Without this structure, pilots can become endless, inconclusive or disconnected from commercial progress.
The goal is not simply to run a pilot.
The goal is to design a pilot that creates evidence, trust and a credible path to adoption.
In practice, this often requires a collaborative model for innovation in health where startups, clinical teams, research institutions and technology partners work together to validate solutions in real healthcare environments.
The role of clinical champions
Healthcare adoption often depends on internal champions.
A founder may sell to an organization, but adoption usually depends on specific people inside that organization who believe the product matters.
Clinical champions can help validate the need, refine the use case, support pilot implementation and build trust with other stakeholders.
However, relying only on individual enthusiasm is risky.
A strong go-to-market strategy should combine champion support with institutional logic.
The product must matter to the champion, but it must also make sense to the organization.
How regulation shapes digital health go-to-market
Regulation affects go-to-market strategy even before formal approval or clearance is required.
The way a product is positioned can influence:
- Sales conversations.
- Institutional trust.
- Investor perception.
- Clinical adoption.
- Partnership opportunities.
If the product may fall under FDA oversight or SaMD classification, the go-to-market strategy must be aligned with the regulatory path.
If the product handles protected health information, HIPAA-aware architecture becomes part of the commercial conversation.
If the product makes claims about outcomes, evidence becomes part of positioning.
In digital health, go-to-market and regulation are connected.
They should not be developed separately.
Early awareness of digital health regulation for startups helps founders understand how FDA considerations, HIPAA compliance, SaMD classification and clinical validation can shape product and market access decisions from the beginning.
Messaging for digital health markets
Digital health messaging must be more precise than generic startup messaging.
Phrases such as “AI-powered”, “revolutionary”, “patient-centric” or “transforming healthcare” are common, but they often fail to communicate what matters.
A stronger message should clarify:
- What problem is being solved.
- Who the product is for.
- What workflow or journey it improves.
- What evidence supports the claim.
- Why the product is viable in healthcare environments.
In healthtech, clarity is stronger than hype.
This is especially important in the US market, where buyers, investors and institutions are exposed to a high volume of digital health claims.
This is why the way founders talk about digital health startups should be aligned with the product’s actual function, evidence stage, regulatory context and adoption pathway.
Common go-to-market mistakes in digital health
Many digital health startups struggle not because the product is weak, but because the go-to-market strategy is underdeveloped.
Common mistakes include:
- Launching without understanding who pays.
- Targeting too many stakeholders at once.
- Treating pilots as informal tests.
- Overclaiming outcomes before evidence exists.
- Assuming hospitals adopt like SaaS customers.
- Delaying reimbursement or regulatory thinking until too late.
These mistakes usually come from applying generic startup logic to a healthcare market.
A better approach is to build the go-to-market strategy around healthcare-specific adoption realities from the beginning.
How a venture studio supports digital health go-to-market
A specialized venture studio can help founders avoid treating go-to-market as a late-stage problem.
At GooVentures, we connect go-to-market thinking with product definition, regulatory awareness, clinical relevance and venture strategy.
This means early decisions are evaluated not only by asking whether the product can be built, but whether it can be adopted, validated, trusted and scaled.
That distinction matters.
A product that is easy to build but hard to adopt is not a strong venture.
A product that is harder to define but aligned with a real healthcare adoption pathway has stronger long-term potential.
This is why a venture studio model for digital health startups can help connect market access, evidence, regulation, product execution and long-term venture strategy from the beginning.
Founders and partners who want to understand how we combine venture strategy, healthcare focus and product execution can learn more about GooVentures and our approach.
Frequently asked questions
What is go-to-market strategy in digital health?
A digital health go-to-market strategy defines how a product enters the healthcare market, who adopts it, who pays for it, what evidence is needed and how it fits into clinical, institutional or commercial workflows.
Why is digital health go-to-market different from SaaS?
Digital health products often involve regulated data, clinical stakeholders, institutional procurement, evidence requirements and complex adoption pathways. This makes go-to-market slower and more stakeholder-dependent than traditional SaaS.
What is the best go-to-market model for a digital health startup?
There is no single best model. Some products are B2C, others are B2B, B2B2C, provider-led, payer-led or partnership-driven. The right model depends on the user, buyer, evidence needs and regulatory profile.
Are pilot programs necessary in digital health?
Not always, but they are often important. Pilots can help demonstrate value, gather evidence, validate workflow fit and build institutional trust before broader deployment.
How does regulation affect go-to-market strategy?
Regulation affects claims, product positioning, institutional conversations, evidence expectations and adoption pathways. FDA, HIPAA, SaMD and clinical validation considerations can all influence go-to-market decisions.
How does GooVentures support digital health go-to-market?
GooVentures helps founders connect product strategy, venture structure, regulatory awareness and market access logic from the beginning, so go-to-market is built into the venture rather than added later.
Build digital health ventures with market access in mind
Digital health go-to-market is not only about growth channels.
It is about building a credible path from product to adoption in one of the most complex markets in the world.
Founders need to understand users, buyers, evidence, workflows, regulation and institutional incentives before they can scale effectively.
At GooVentures, we treat go-to-market as part of venture building. A strong digital health startup is not only one that can build a product, but one that can enter the healthcare system with clarity, trust and strategic discipline.
Because in digital health, market access is not a final step. It is part of how the company must be built from day one.
